S&P Futures
6,011.50 -4.50 (-0.07%) Dow Futures
44,086.00 -22.00 (-0.05%) Nasdaq Futures
21,131.00 -28.50 (-0.13%) Russell 2000 Futures
2,379.30 -3.40 (-0.14%) Crude Oil
68.28 -0.15 (-0.22%) Gold
2,567.70 -18.80 (-0.73%)
Virpax Pharmaceuticals, Inc. (VRPX)
After hours:
| Previous Close | 0.6201 |
| Open | 0.5700 |
| Bid | 0.5890 x 100 |
| Ask | 0.6810 x 100 |
| Day's Range | 0.5512 - 0.6500 |
| 52 Week Range | 0.3630 - 8.0000 |
| Volume | |
| Avg. Volume | 283,553 |
| Market Cap | 3.031M |
| Beta (5Y Monthly) | 1.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -13.2500 |
| Earnings Date | May 18, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
- Business Wire
Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
BERWYN, Pa., November 13, 2024--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the pricing of its public offering of $5.0 million of shares of the Company’s common stock, par value 0.00001 per share, and/or pre-funded warrants to purchase shares of common stock at a public offering price of $0.50 per share (minus $0.00001 per
GlobeNewswireAdial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer
GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company’s Chief Financial Officer, effective November 16, 2024. Vinay Shah is an accomplished Chief Financial Officer with over 25 years of experience in the pharmaceutical, biophar
